Press releases

Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate

Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated

Oxford BioTherapeutics Expands Strategic Collaboration with  WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi

Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform

Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours

Oxford BioTherapeutics  enters into Commercial License Agreement with Genmab

Oxford BioTherapeutics  Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

Oxford BioTherapeutics Announced Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers

Oxford BioTherapeutics  relocates UK Headquarters to strategic and cutting-edge R&D location at the Oxford Science Park to accelerate development of its immuno-oncology and ADC-based cancer therapies​

Oxford BioTherapeutics  Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers​

Oxford BioTherapeutics  to Participate in Panel Discussion at Boehringer Ingelheim's upcoming Transforming Science Day: Europe